Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Follow-On Biologics Pathway Unlikely Without Confirmed FDA Commissioner

Executive Summary

FDA is unlikely to proceed with developing a follow-on biologics pathway until a permanent commissioner is confirmed, a Senate Health Committee staffer said at a Food & Drug Law Institute conference in Washington, D.C., Nov. 16

You may also be interested in...



Von Eschenbach’s FDA Will Be A “Facilitating Agency,” Nominee Says

FDA Commissioner-nominee Andrew von Eschenbach plans to use the agency as an engine to help drive product development

Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works

Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda

Drug Safety Stays At Top Of FDA’s Agenda With New Guidances In The Works

Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda

Related Content

Topics

UsernamePublicRestriction

Register

PS046593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel